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doi:10.1016/j.ejvs.2011.01.001Abstract Background: Recent randomised controlled trials comparing carotid artery stenting
(CAS) with endarterectomy (CEA) for the treatment of symptomatic carotid stenosis were not
powered to investigate differences in risks in specific patient subgroups. We therefore per-
formed a pooled analysis of individual patient data from the Symptomatic Severe Carotid
Stenosis trial (EVA-3S), the Stent-Protected Angioplasty versus Carotid Endarterectomy trial
(SPACE), and the International Carotid Stenting Study (ICSS).
Methods: Individual data from all 3433 patients randomised and analysed in these trials were
pooled and analysed with fixed-effect binomial regression models adjusted for source trial.
The primary outcome event was any stroke or death.
Results: In the first 120 days after randomisation (ITT analysis), the primary outcome event
occurred in 153/1725 patients in the CAS group (8.9%) compared with 99/1708 patients in
the CEA group (5.8%, risk ratio [RR] 1.53, 95% confidence interval [CI] 1.20e1.95,
pZ 0.0006; absolute risk difference 3.2, 95% CI 1.4e4.9). Age was the only subgroup variable
which significantly modified the treatment effect: in patients <70 years old (the median age),
the 120-day stroke or death risk was 5.8% in CAS and 5.7% in CEA (RR 1.00, 0.68e1.47); in
patients 70 years or older, there was an estimated two-fold increase in risk with CAS over
CEA (12.0% vs. 5.9%, RR 2.04, 1.48e2.82, interaction p Z 0.0053).
Interpretation: Endarterectomy was safer in the short-term than stenting, because of an
increased risk of stroke associated with stenting in patients over the age of 70 years. Stenting
should be avoided in older patients, but may be as safe as endarterectomy in younger patients.
Determination of the efficacy and ultimate balance between the two procedures requires
further data on long-term stroke recurrence.
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154 L.H. Bonati, G. FraedrichIntroduction In the ITT analysis, the interactions between the effectIn patients with recently symptomatic carotid stenosis,
carotid endarterectomy reduces the risk of further
stroke.1,2 In recent years, endovascular treatment with
placement of a stent has emerged as an alternative option
to treat carotid stenosis. Several large trials in patients
with symptomatic carotid stenosis who could undergo
surgery at standard risk e the Endarterectomy versus
Angioplasty in Patients with Symptomatic Severe Carotid
Stenosis trial (EVA-3S), the Stent-Protected Angioplasty
versus Carotid Endarterectomy trial (SPACE) and the
International Carotid Stenting Study (ICSS) e have shown
a higher peri-procedural stroke risk with stenting than with
endarterectomy.3e5 However, peri-procedural risks of
stenting and endarterectomy vary with patient character-
istics.6e9 Stenting might represent a safe alternative to
endartererctomy in specific groups of patients, but no
single trial was large enough to compare the risks between
these procedures with an acceptable degree of certainty.
With these considerations in mind, the investigators of
EVA-3S, SPACE, and ICSS set up the Carotid Stenting Tria-
lists’ Collaboration (CSTC) with the purpose of conducting
a prospective meta-analysis of individual patient data from
these trials. The main objective was to compare the safety
and efficacy of stenting and endarterectomy in pre-defined
subgroups of patients. In this report, we summarise the
main results of the analysis of the short-term (safety)
outcome. The full results of this analysis were published in
The Lancet in September 2010.10
Methods
EVA-3S (NCT 00190398), SPACE (ISRCTN 57874028), and ICSS
(ISRCTN 25337470) were randomised clinical trials with
blinded outcome adjudication. In all three trials, patients
with recently symptomatic moderate or severe carotid
stenosis (50% reduction of the lumen diameter according to
themethod used in the NASCET Trial1), who were considered
equally suited for eitherprocedure,were randomlyallocated
to undergo treatment by stenting or endarterectomy.11e13
The pooled analysis of individual patient data was prospec-
tively agreed at the design stage of these trials.14
The primary outcome event for the pooled analysis of
short-term outcome was the combination of any stroke or
death. Secondary major outcome events were disabling
stroke or death, all-cause death, and any stroke. The
intention-to-treat (ITT) analysis included all patients
randomised and analysed in the contributing trials and all
outcome events occurring between randomisation and
120 days thereafter. The per-protocol (PP) analysis
included only those patients who received the randomly
allocated treatment as the first initiated revascularisation
procedure after randomisation. Only outcome events
occurring between the first treatment and 30 days
thereafter were included in the PP analysis. The pooled
data were analysed with fixed-effect binomial regression
models including source trial terms as covariables, to
obtain overall estimates of risk ratios (RR) and risk
differences (RD) with 95% confidence intervals (CI) of
major outcome events.of treatment on the primary outcome event and 16
prospectively defined subgroup variables were examined
separately in the binomial regression model. These
subgroup variables were age; sex; history of diabetes,
hypertension, hypercholesterolaemia, smoking, coronary
heart disease, and peripheral artery disease; type of the
qualifying event (retinal ischaemia including transient
monocular blindness or retinal infarct, hemispheric tran-
sient ischaemic attack, or hemispheric ischaemic stroke);
history of stroke before the most recent ipsilateral
ischaemic event; systolic blood pressure at randomisation;
degree of ipsilateral carotid stenosis (moderate, 50e69%;
or severe, 70e99%), and contralateral severe carotid
stenosis or occlusion; centre contribution (total number of
patients recruited into a trial at the centre), and centre
recruitment rate (average number of patients recruited per
month). Significant subgroup-treatment effect interactions
identified in the ITT analysis were also examined in the PP
analysis. In addition, the interaction with the delay
between the qualifying event and treatment was assessed
in the PP analysis.Results
All 3433 patients (1725 in the stenting group and 1708 in the
endarterectomy group) who were randomised and followed
up in the contributing trials were included in the pooled ITT
analysis. The PP analysis comprised 3324 patients who
underwent stenting (n Z 1679) or endarterectomy
(n Z 1645), as their randomly allocated revascularisation
procedure. Patient baseline characteristics were similar in
the two treatment groups (Table 1).
Risk ratios and numbers of major outcome events in the
pooled ITT analysis are provided in Table 2. The risk of any
stroke or death occurring within 120 days of randomisation
was 8.9% in the stenting group and 5.8% in the endarter-
ectomy group (RR 1.53, 95% CI 1.20e1.95, pZ 0.0006). This
effect was mainly driven by a significant difference in
stroke risk (8.2% vs. 4.9%, RR 1.66, 1.28e2.15, pZ 0.0001).
Among the different subtypes of stroke severity, the largest
difference was observed in the occurrence of non-disabling
strokes, which were twice as frequent in the stenting group
as in the endarterectomy group (4.2% vs. 2.1%, RR 1.99,
1.34e2.95, p Z 0.0004). There were no statistically
significant differences in the secondary outcome events of
disabling stroke or death (4.8% vs. 3.7%, RR 1.27,
0.92e1.74) and all-cause death (1.9% vs. 1.3%, RR 1.44,
0.84e2.47).
The 30-day PP analysis produced similar results to the
120-day ITT analysis (Table 3): the risk of any stroke or
death occurring between treatment and 30 days thereafter
was 7.7% in the stenting group compared with 4.4% in the
endarterectomy group (RR 1.74, 1.32e2.30). In the PP
analysis, the difference between the procedures in
disabling stroke or death, which also favoured surgery,
became significant (3.9% vs. 2.6%, RR 1.48, 1.01e2.15, pZ
0.04). There was no difference in the risk of myocardial
infarction which occurred in 0.2% of patients receiving
stent treatment and 0.4% of patients undergoing surgery.
Cranial nerve palsy almost exclusively occurred in patients
Table 1 Baseline data of the combined trial populations.
CAS
(n Z 1725)
CEA
(n Z 1708)
N, mean
or median
%, SD or
IQR
N, mean
or median
%, SD or
IQR
Age at randomisation, years (mean, SD) 69.3 9.0 69.7 9.2
Male (N, %) 1230 71% 1232 72%
History of diabetes (N, %) 400 23% 423 25%
History of hypertension (N, %) 1235 72% 1234 73%
Systolic blood pressure at randomisation, mm Hg (mean, SD)a 144.7 21.2 143.7 21.1
History of hypercholesterolaemia (N, %)b 676 61% 708 64%
Any smoking history (current or past) (N, %) 1106 64% 1095 64%
Current smoking (N, %) 430 25% 424 25%
History of coronary heart disease (N, %) 409 24% 420 25%
History of peripheral artery disease (N, %)b 179 16% 166 15%
Type of most recent ipsilateral ischaemic
event before randomisation (N, %)
Retinal ischaemia 310 18% 297 18%
TIA 589 34% 601 35%
Hemispheric stroke 813 47% 797 47%
History of stroke before most recent event (N, %)b 190 17% 180 16%
Days elapsed between most recent event and
randomisation (median, IQR)c
19 7.0e50.0 19 9.0e53.0
Randomisation within 14 days of most recent event (N, %)c 587 40% 577 40%
Days elapsed between most recent event and treatment
(median, IQR)c,d
29 14e65 32 15e71
Treatment within 14 days of most recent eventc,d 372 26% 315 22%
Score on the Modified Rankin Scale at
baseline (N, %)e
0 826 48% 772 46%
1 461 27% 446 26%
2 295 17% 330 19%
3 107 6% 126 7%
4 19 1% 17 1%
5 1 0% 3 0%
Degree of ipsilateral carotid stenosis (N, %)f Moderate (50e69%) 332 19% 327 19%
Severe (70e99%) 1393 81% 1381 81%
Contralateral severe carotid stenosis (70%) or occlusion (N, %) 235 15% 235 15%
Number of patients recruited per centre (median, IQR) 52 (29.0e108.0)
Centre recruitment rate (average number of patients recruited
per month; median, IQR)
1.1 (0.7e1.7)
BP, blood pressure; CAS, Carotid stenting; CEA, carotid endarterectomy; IQR, interquartile range; SD, standard deviation. Percentages
exclude missing data.
a Rounded to nearest 5 mm Hg due to digit preference.
b Data collected in EVA-3S and ICSS only.
c The date of the most recent ipsilateral ischaemic event before randomisation was not collected in the SPACE trial initially, but for the
meta-analysis these dates (or if the exact date was unknown, whether or not randomisation and treatment took place within 14 days of
the qualifying event), were retrieved where available.
d Patients receiving the randomly allocated treatment only (per-protocol-analysis).
e Modified Rankin Scores at baseline may reflect non-stroke impairments; protocols of contributing trials excluded patients with
disabling strokes.
f Degree of stenosis measured by NASCET method or equivalent non-invasive method.
A Pooled Analysis of EVA-3S, SPACE and ICSS 155treated surgically (6.0%), and wound haematoma was also
more common in the endarterectomy group (Table 3).
There was a statistically significant interaction between
age and the effect of treatment on the primary outcome
event. In the ITT analysis, the estimated 120-day risks of any
stroke or death in patients <70 years old were 5.8% in the
stenting group and 5.7% in endarterectomy group (RR 1.00,
0.68e1.47); in patients 70 years or older, there was an esti-
mated two-fold increase in the risk of stroke or death withstenting over endarterectomy (12.0% vs. 5.9%, RR 2.04,
1.48e2.82, interaction p Z 0.0053). No other subgroups
showed statistically significant interactionswith treatment on
theprimaryoutcomeevent.Agealso significantlymodifiedthe
effect of treatment on disabling stroke or death (<70 years:
2.5% (CAS) vs. 3.6% (CEA), RR 0.71, 0.41e1.22;70 years: 7.0%
vs. 3.9%, RR 1.78, 1.18e2.68; interaction pZ 0.0071).
In an exploratory post-hoc analysis, risk ratios of the
primary outcome event across six age groups were broadly
Table 2 Outcome events occurring within 120 days of randomisation (intention-to-treat analysis).
CAS
n Z 1725
N events (%a)
CEA
n Z 1708
N events (%a)
Risk ratiob
(95% CI)
p-Valuec Risk
differenceb
(95% CI)
Any stroke or death 153 (8.9%) 99 (5.8%) 1.53 (1.20, 1.95) 0.0006 3.2 (1.4, 4.9)
Disabling stroke or death 82 (4.8%) 64 (3.7%) 1.27 (0.92, 1.74) 0.15 0.9 (0.4, 2.3)
All-cause death 32 (1.9%) 22 (1.3%) 1.44 (0.84, 2.47) 0.18 0.7 (0.2, 1.5)
Any stroke 141 (8.2%) 84 (4.9%) 1.66 (1.28, 2.15) 0.0001 3.3 (1.7, 5.0)
Stroke severityd
Fatal stroke 13 (0.8%) 6 (0.4%) 2.15 (0.82, 5.65) 0.11 0.4 (0.1, 0.9)
Disabling stroke 56 (3.2%) 43 (2.5%) 1.29 (0.87, 1.90) 0.21 0.5 (0.5, 1.6)
Non-disabling stroke 72 (4.2%) 36 (2.1%) 1.99 (1.34, 2.95) 0.0004 2.0 (0.8, 3.2)
Stroke pathologye
Ischaemic stroke 135 (7.8%) 71 (4.2%) 1.88 (1.42, 2.48) <0.0001 3.8 (2.2, 5.4)
Haemorrhagic stroke 6 (0.3%) 11 (0.6%) 0.54 (0.20, 1.46) 0.21 0.3(0.8,0.1)
Unknown pathology 0 2 (0.1%) ef ef ef
Stroke territorye
Ipsilateral carotid 126 (7.3%) 75 (4.4%) 1.66 (1.26, 2.19) 0.0003 3.0 (1.4, 4.5)
Contralateral carotid or
vertebrobasilar
13 (0.8%) 9 (0.5%) 1.43 (0.61, 3.34) 0.40 0.2 (0.3, 0.8)
Unknown territory 2 (0.1%) 0 ef ef ef
CAS, carotid stenting; CEA, carotid endarterectomy; CI, confidence interval.
a Crude percentages (number of events divided by number of patients).
b Adjusted for source trial.
c P-values derived from binomial regression likelihood ratio test, adjusted for source trial.
d One patient in the endarterectomy group had two stroke events within the 120 day period after randomisation.
e Stroke pathology and stroke territory refer to first event.
f Adjusted risk ratio or risk difference and CI not estimated as model did not converge.
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age on the log risk ratios, with treatment effects favouring
endarterectomy more strongly with increasing age
(p Z 0.0015 for trend interaction across age groups).
The interaction between age and the effect of treat-
ment on the primary outcome event was also significant in
the PP analysis: Risk estimates of stroke or death within 30
days of treatment among patients <70 years old were 5.1%
in the stenting group and 4.5% in the endarterectomy group
(RR 1.11, 0.73, 1.71); in the subgroup of 70 year olds risk
estimates were 10.5% and 4.4%, respectively (RR 2.41,
1.65e3.51; interaction p Z 0.0078).
Discussion
This prospective pooled analysis of individual patient data
from the EVA-3S, SPACE and ICSS trials confirmed an
increased short-term risk of any stroke or death among
patients randomised to stenting compared with endarter-
ectomy. However, the relative harm of stenting strongly
depended on age: risks of stroke or death in patients younger
than 70 years old were similar in the two treatment groups;
by contrast, there was a two-fold increase in the risk of
stenting compared with endarterectomy among patients
70 years old. The difference in the primary endpoint was
mainly attributed to a higher risk of non-disabling strokes,
which occurred twice as often in the stenting group as in the
endarterectomy group (4.2 vs. 2.1%). The difference in risk
of disabling stroke or deathwas not statistically significant in
the ITT analysis (4.8 vs. 3.7%) but reached statistical signif-
icance in the PP analysis (3.9 vs. 2.6%).In the Carotid Revascularization Endarterectomy vs.
Stenting Trial (CREST) there was no significant difference
between these two procedures in the combined primary
outcome measure of any peri-procedural stroke, MI, or death,
or ipsilateral stroke during a median follow-up of 2.5 years.15
The main difference between CREST and the trials included
in the present pooled analysis was that CREST enrolled both
patientswith symptomatic andasymptomatic carotid stenosis.
Yet among the1321patientswith symptomatic carotid stenosis
in CREST, the risk of any stroke or death between random-
isation and 30 days after treatment was significantly higher in
the stenting than in the surgery arm (6.0% vs. 3.2%); the cor-
responding hazard ratio of 1.89 (95% confidence interval
1.11e3.21) was very similar to the treatment effect observed
in our pooled analysis.
The main advantage of the present meta-analysis was
the availability of individual patient data. Pooling these
data from three randomised trials allowed for a much
higher statistical power to perform subgroup analysis.
Among the prespecified list of 16 subgroup variables, age
was the only one which significantly altered the relative risk
of stroke or death between stenting and endarterectomy in
the short term. Whereas risk estimates were similar with
both treatments among patients <70 years old, a two-fold
increase in risk with stenting over endarterectomy was
observed in the older age group. Age also significantly
modified the effect of treatment on disabling stroke or
death. The exploratory analysis of relative treatment risks
across six age level was consistent with the assumption of
a linear increase in risk of peri-procedural stroke risk
associated with stent treatment. Possible mechanisms
Table 3 Outcome events occurring within 30 days of treatment (per-protocol-analysis).
CAS
n Z 1679
N events (%a)
CEA
n Z 1645
N events (%a)
Risk ratiob
(95% CI)
p-Valuec Risk
differenceb
(95% CI)
Any stroke or death 130 (7.7%) 73 (4.4%) 1.74 (1.32e2.30) 0.0001 3.4 (1.8, 5.0)
Disabling stroke or death 65 (3.9%) 43 (2.6%) 1.48 (1.01e2.15) 0.04 1.2 (0.0, 2.4)
All-cause death 19 (1.1%) 10 (0.6%) 1.86 (0.87e4.00) 0.10 0.6 (0.1, 1.2)
Any stroke 125 (7.4%) 70 (4.3%) 1.74 (1.31e2.32) 0.0001 3.3 (1.7, 4.9)
Stroke severityd
Fatal stroke 12 (0.7%) 6 (0.4%) 1.97 (0.74, 5.23) 0.16 0.4 (0.1, 0.8)
Disabling stroke 47 (2.8%) 34 (2.1%) 1.35 (0.87, 2.08) 0.18 0.6 (0.4, 1.6)
Non-disabling stroke 66 (3.9%) 31 (1.9%) 2.09 (1.37, 3.19) 0.0004 2.0 (0.8, 3.2)
Stroke pathologye
Ischaemic stroke 118 (7.0%) 57 (3.5%) 2.02 (1.48, 2.75) <0.0001 3.7 (2.2, 5.2)
Haemorrhagic stroke 7 (0.4%) 12 (0.7%) 0.57 (0.23, 1.45) 0.23 0.3 (0.8, 0.1)
Unknown pathology 0 1 (0.1%) ei ei ei
Stroke territorye
Ipsilateral carotid 113 (6.7%) 66 (4.0%) 1.67 (1.24, 2.25) 0.0005 2.8 (1.3, 4.3)
Contralateral carotid or vertebrobasilar 10 (0.6%) 4 (0.2%) 2.45 (0.77, 7.81) 0.11 0.4 (0.1, 0.8)
Unknown territory 2 (0.1%) 0 ei ei ei
Myocardial infarction 4 (0.2%) 7 (0.4%) ei ei ei
Non-fatal myocardial infarction 1 (0.1%) 7 (0.4%) ei ei ei
Fatal myocardial infarction 3 (0.2%) 0 ei ei ei
Cranial nerve palsyf 7 (0.4%) 99 (6.0%) 0.07 (0.03, 0.15) <0.0001 5.6 (6.7, 4.4)
Severe haematomag 12 (0.7%) 32 (1.9%) 0.37 (0.19, 0.71) 0.0016 ei
Severe wound infectionh 1 (0.1%) 4 (0.2%) ei ei ei
CAS, carotid stenting; CEA, carotid endarterectomy; CI, confidence interval.
a Crude percentages (number of events divided by number of patients).
b Adjusted for source trial.
c p-Values derived from binomial regression likelihood ratio test, adjusted for source trial.
d One patient in the endarterectomy group had two stroke events within 30 days after treatment.
e Stroke pathology and stroke territory refer to first event.
f In the stenting group, cranial nerve palsy (CNP) was caused by carotid artery dissection in 2 patients; in 3 patients, CNP occurred
after conversion to endarterectomy following unsuccessful initial attempts at stenting; and 2 patients had isolated dysphagia attrib-
utable to CNP following stent procedures.
g Defined as neck haematoma after endarterectomy or haematoma at the site of puncture after stenting, which required surgery or
blood transfusion, or which prolonged hospital stay.
h Defined as any infection at the site of surgery or skin puncture in stenting, which required antibiotic treatment or surgery, or which
prolonged hospital stay.
i Adjusted risk ratio or risk difference and CI not estimated as model did not converge.
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of atherosclerosis, changes in plaque characteristics, or
changes in vascular anatomy with increasing age, which
may each increase the risk for thromboembolism during
catheterisation or stent deployment.
What are the implications of our findings for clinical
practice? Results from single clinical trials and previous
summarydatameta-analyses havenot justifiedany change in
policy of recommending endarterectomy as the treatment of
choice for symptomatic carotid stenosis. Current recom-
mendations have therefore limited the use of stenting to
patients with symptomatic carotid stenosis who had contra-
indications to surgery, and those with stenosis at surgically
inaccessible sites, recurrent stenosis after previous endar-
terectomy, or post-irradiation stenosis.16 The present results
now suggest that stentingmay represent a safe alternative to
endarterectomy in younger patients, who could otherwise
undergo surgery without increased risk. Some uncertainty
remains regarding the potentially higher rate of recurrent
stenosis after stenting compared with endarterectomy, andthe implications this may have for long-term stroke risk in
youngpatients treatedwith stents.17,18With these caveats in
mind, an approach of offering stenting where technically
feasible as an alternative option to endarterectomy to
patients with symptomatic carotid stenosis below 65e70
years of age, in centres where acceptable peri-procedural
outcomes have been independently verified, may seem
justified, as long as patients are made aware of a possible
increase in the risk of restenosis.
Our study has some limitations. Even with the pooled
analysis of three randomised trials, statistical power to test
for interactions with some patient subgroups where stent-
ing may theoretically represent a safe alternative to
endarterectomy, may have been too low. The contributing
trials did not specify imaging of the aortic arch prior to
randomisation. The exact number of procedures performed
by individual surgeons and interventionalists before joining
the trials has not been consistently collected in the
contributing trials, and the impact of individual experience
on complication rates requires further investigation.
158 L.H. Bonati, G. FraedrichHowever, the prospectively defined meta-analysis of EVA-
3S, SPACE and ICSS yielded a highly significant result of an
age-dependent variation of treatment risks posed by
stenting which has implications for clinical practice.
In conclusion, there is strong evidence that in the short-
term, the relative harm of stenting compared with endar-
terectomy decreases with younger age.
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